28 June - 1 July 2017
Barcelona, Spain

Scientific Agenda

Skip to Day 2: Thursday, 29 June 2017

Skip to Day 3: Friday, 30 June 2017

Skip to Day 4: Saturday, 1 July 2017

 

Wednesday, 28 June 2017

12:30

Expert discussion (by invitation only)
Scientific Committee and Selected Experts

13:30

Concurrent lunch mini-symposia begin

14:30

Concurrent lunch mini-symposia adjourn

Session I: Opening, Selected Abstracts, and Opening Lectures

14:45

Welcome and Introduction

14:50

Presentation of selected abstracts

15:15

Opening Lecture: The role of the microbiome in cancer medicine
Speaker invited

Session II: Cancer of the Pancreas and Bile Ducts

16:10

Clinical implications of the progress in understanding the biology of pancreatic cancer
Speaker invited

16:30

Screening in familial and hereditary pancreatic cancer
Margaret A. Tempero, MD

16:45

Presentation of selected abstract

16:55

Is adjuvant or neo-adjuvant treatment for pancreatic cancer the way to go?
Speaker invited

17:25

Diagnostic modalities for defining resectability (CT, EUS, MRI)
Speaker invited

17:45

Presentation of selected abstracts

18:05

Improving the outcome of patients with metastatic pancreatic cancer
Speaker invited

18:25

New agents/strategies on the horizon in pancreatic cancer
Philip A. Philip, MD, PhD, FRCP

18:45

Adjourn

19:00

Concurrent evening non-profit symposia begin

20:30

Concurrent evening non-profit symposia adjourn

20:30

Welcome reception


Thursday, 29 June 2017

7:00

Concurrent industry breakfast lectures begins

7:45

Concurrent industry breakfast lectures adjourn

Session III: Meet the Expert Concurrent Presentations

Parallel with Session IV: Interpreting Clinical Trials Results

08:00

Anal cancer
Michel Ducreux, MD, PhD and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
Jordan D. Berlin, MD and Thomas Gruenberger, MD

Implementation of a wait and see program for rectal cancer: Pitfalls
Andre D'Hoore, MD, PhD and Rodrigo Perez, MD

Recent advances in management of GIST
Speaker invited

Thrombosis and cancer
Mario Dicato, MD

Session IV: Interpreting Clinical Trials Results

Parallel with Session III: Meet the Expert Concurrent Presentations

08:00

Statistical interpretation and validity of clinical trials
Speaker invited

08:20

Clinical interpretation and validity of clinical trials: When do they become practice changing?
Alberto Sobrero, MD

08:40

How relevant are the ESMO and ASCO clinical benefit scales: Do they impact our practice?
Fortunato Ciardiello, MD, PhD

09:10

Biosimilars: How much evidence do we need?
Mario Dicato, MD

Session V: Esophageal and Gastric Cancers

09:00

Managing early esophageal cancer endoscopically
Speaker invited

09:20

Minimally invasive surgery for cancer of the esophagus
Christophe Mariette, MD, PhD

09:40

New evolutions for the neo-adjuvant and adjuvant treatment of esophageal cancer
Florian Lordick, MD, PhD

10:00

Presentation of selected abstract

10:10

Gastric carcinogenesis of gastric cancer through the eyes of a pathologist
Fatima Carneiro, MD, PhD

10:30

Keynote Lecture 1: Progress in unraveling the molecular taxonomy in gastric cancer
Patrick Tan, MD, PhD

11:00

Break and poster viewing
Posters to be presented: Clinical/basic non-CRC abstracts
Poster discussion guided tours

Session VI: Gastric Cancer

11:30

Neo-adjuvant/Adjuvant treatment in gastric cancer: What is optimal approach in 2017? Case based discussions
Ian Chau, MD

11:50

Presentation of selected abstracts

12:20

Metastatic gastric cancer: What are the indications and what is the impact of targeting the HER2 pathway?
Andrés Cervantes, MD, PhD

12:30

Metastatic gastric cancer: What are the indications and what is the impact of angiogenesis inhibitors?
Speaker invited

12:40

Metastatic gastric cancer: What are the indications and what is the impact of check-point inhibitors?
Kohei Shitara, MD

12:50

Metastatic gastric cancer: What are the indications and what is the impact of stem-cell inhibition
Julien Taieb, MD

13:10

Session adjourns

13:30

Concurrent luncheon symposia begin

15:00

Concurrent luncheon symposia adjourn

Session VII: Frequently Asked Clinical Questions/Challenges

15:10

Hepatitis B and C testing and treatment of flare up in GI oncology
Speaker invited

15:30

IBD related GI cancers: Are they different?
Speaker invited

15:45

How to do MSI testing?
Pierre Laurent-Puig, MD, PhD

16:00

When and how do go BRCA testing in GI cancer and what are the implications?
Judith Balmaña, MD, PhD

16:20

Presentation of selected abstracts

16:50

Break and poster viewing
Posters to be presented: Clinical/Basic non-CRC abstracts

Session VIII: Rare Tumors: Neuroendocrine Tumors and hepatocellular Cancer

17:20

Controversy debate: Targeted agents versus PRRT in NET: Case scenarios

Targeted agents first
Speaker invited

PRRT first
Jonathan Strosberg, MD

17:50

Pathological classification of NET
Aurel Perren, MD

18:10

Controversy debate: Hepatocellular carcinoma: Case scenarios

Medical treatment first:
Jordi Bruix, MD

Locoregional treatment first
Michel Ducreux, MD, PhD

18:40

New targets and new agents in HCC
Speaker invited

19:00

Adjourn

19:15

Concurrent evening symposia begin

20:45

Concurrent evening symposia adjourn


Friday, 30 June 2017

Session IX: Meet the Expert Concurrent Presentations

Parallel with Session X: Presentation of Selected Abstracts: Colorectal Cancer, Session XI: Presentation of Selected Abstracts: Miscellaneous, and Session XII: ESMO Session: Focus on Young Medical Oncologists

08:00

Carcinoma of unknown origin
George Pentheroudakis, MD

Teaching the basics of radiotherapy: IMRT, SBRT, protontherapy
Karin Haustermans, MD, PhD

Treatment of elderly patients with GI cancer
Demetris Papamichael, MB, BS

Workshop: Liver directed therapies: Radioembolisation, chemoembolization and surgery for metastatic CRC: Case based session
Bernard Nordlinger, MD and Julien Taieb, MD, PhD

Session X: Presentation of Selected Abstracts- Colorectal Cancer

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session XI: Presentation of selected Abstracts: Miscellaneous

08:00

Presentation of selected abstracts

09:10

Session adjourns

Session XI: Presentation of Selected Abstracts: Miscellaneous

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer

08:00

Presentation of selected abstracts

09:10

Session adjourns

Session XII: ESMO Session: Focus on Young Medical Oncologists

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer, and Session XI: Presentation of Selected Abstracts: Miscellaneous

Part 1: Career Development

08:00

How to develop a career path in the current panorama of GI oncology in Europe
Fotios Loupakis, MD

08:20

The importance of mentorship in the European environment
Dirk Arnold, MD, PhD

Part 2: Scientific Session

08:40

Liquid biopsies in managing CRC: Are we ready for prime time?
Speaker invited

09:00

Next frontiers in BRAF therapeutics
Elena Elez, MD, PhD

9:20

Session adjourns

Session XIII: From Epidemiology to Prevention of GI Cancer

09:15

Is the epidemiology of CRC and other GI cancers changing?
Speaker invited

09:30

Recommendations for surveillance of adenomas
Jaroslaw Regula, MD

09:50

Can we improve screening methods of colorectal cancer?
Nadir Arber, MD, MHA

10:10

Are we understanding better the adenoma - carcinoma transition?
Eduardo Vilar Sanchez, MD, PhD

10:30

Travel grant award ceremony

10:35

Break and poster viewing
Posters to be presented: Clinical/Basic CRC abstracts
Poster discussion guided tours

Session XIV: Multimodality Therapy for Rectal Cancer

11:05

Organ preservation in rectal cancer: How and for whom?
Rodrigo Perez, MD

11:25

Advances and challenges in the surgical treatment of locally advanced rectal cancer
Andre D'Hoore, MD, PhD

11:45

Defining the strategy in oligometastatic rectal cancer

The oncologists point of view
Dirk Arnold, MD, PhD

The surgeon's point of view
Bernard Nordlinger, MD

The radiation oncologist point of view
Felipe A. Calvo, MD

12:25

Presentation of selected abstracts

13:00

Session Adjourns

13:20

Concurrent luncheon symposia begin

14:50

Concurrent luncheon symposia adjourn

Session XV: Immune Mechanisms and Immune Therapy in GI Cancer

15:00

Keynote Lecture 2: Understanding the relevant immune mechanisms in GI cancer
Pierre Coulie, MD, PhD

15:30

The immune and stromal classification of colorectal cancer
Wolf H. Fridman, MD, PhD

15:50

Molecular classification of colon cancer: New insights
Sabine Tejpar, MD, PhD

16:10

Does the molecular and immunologic classifications have clinical implications in 2017?
Rodrigo Dienstmann, MD

16:30

Discussion

16:40

Break and poster viewing
Abstracts to be presented: Clinical/Basic CRC abstracts

Session XVI: Molecular Biology in CRC

17:10

How to approach the patient with a BRAF mutant tumor?
Speaker invited

17:30

Acquired resistance to EGFR antibodies: How to manage?
Federica Di Nicolantonio, MD

17:50

Immune therapy in CRC
Speaker invited

18:00

Immune therapy in non-CRC GI cancer
Speaker invited

18:10

Current status and perspectives on liquid biopsies in mCRC
Scott Kopetz, MD, PhD, FACP

Session XVII: Highlights of ASCO and ESMO GI Abstracts

18:30

Selected abstracts: Highlights of poster discussions and posters at ESMO GI

19:00

Adjourn


Saturday, 1 July 2017

Session XVIII: Colorectal Cancer: Tumor Board

08:30

Multidisciplinary tumor board on resectable and borderline/potentially resectable liver metastases
Speaker invited

09:00

Molecular and hereditary tumor board
Speaker invited

Session XIX: Colorectal Cancer

09:30

Controversy debate: Updates on treatment algorithms in metastatic CRC in 2017

The ESMO guidelines on metastatic CRC
Eric Van Cutsem, MD, PhD

NCCN guidelines
Alan P. Venook, MD

Asian guidelines
Takayuki Yoshino, MD

The left versus right colon cancer story: What is the truth
Speaker invited

10:25

Break

10:55

Can we refine the selection for adjuvant treatment in colon cancer?
Aimery De Gramont, MD

11:15

Presentation of selected abstracts

12:55

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XX: Future of GI Oncology

14:55

The surgeon of the future
Speaker invited

15:05

The GI endoscopist in the future
Speaker invited

15:15

The GI oncologist of the future
Speaker invited

15:25

The radiation oncologist of the future
Speaker invited

15:35

The pathologist of the future
Fatima Carneiro, MD

15:45

The radiologist in the future
Speaker invited

15:55

The nuclear medicine physician of the future
Christophe Deroose, MD, PhD

Session XXII: Report on Expert Discussion

16:15

Presentation of outcome of expert discussion
Eric Van Cutsem, MD, PhD, Josep Tabernero, MD, PhD, Mario Dicato, MD